29513-50-6

Usage

Uses

Used in Polymer Synthesis:
N-Acryloyl-2-methylalanine is used as a monomer for the synthesis of polymers and copolymers, which are essential in the production of various industrial materials. Its properties contribute to the development of adhesives, coatings, and other products that require specific adhesive or film-forming characteristics.
Used in Biomedical Applications:
In the biomedical field, N-Acryloyl-2-methylalanine is utilized for its biocompatibility and potential in creating controlled release systems. It is being studied for use in drug delivery systems and biomedical implants, where its controlled release properties could enhance the efficacy and safety of medical treatments.
Used in Adhesives Industry:
N-Acryloyl-2-methylalanine is used as a component in the formulation of adhesives, where its ability to form strong bonds with various substrates is leveraged to improve the performance of adhesive products.
Used in Coatings Industry:
N-Acryloyl-2-methylalanine is also used in the development of coatings, where its film-forming properties contribute to the creation of durable and protective layers on different surfaces.
Further research is necessary to fully explore the potential applications and properties of N-Acryloyl-2-methylalanine, ensuring that its use in these industries is optimized and safe.

InChI:InChI=1/C7H11NO3/c1-4-5(9)8-7(2,3)6(10)11/h4H,1H2,2-3H3,(H,8,9)(H,10,11)

Upstream product

• 86350-96-1 2-acrylamido-2-methylpropionitrile 
• 62-57-7 2-Aminoisobutyric acid 
• 814-68-6 acryloyl chloride 

Downstream Products

• 29513-26-6 vinyl azlactone 

Relevant academic research and scientific papers

The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension

Polymeric nanoparticles are designed to transport and deliver nitric oxide (NO) into hepatic stellate cells (HSCs) for the potential treatment of both liver fibrosis and portal hypertension. The nanoparticles, incorporating NO donor molecules (S-nitrosoglutathione compound), are designed for liver delivery, minimizing systemic delivery of NO. The nanoparticles are decorated with vitamin A to specifically target HSCs. We demonstrate, using in vitro and in vivo experiments, that the targeted nanoparticles are taken up specifically by rat primary HSCs and the human HSC cell line accumulating in the liver. When nanoparticles, coated with vitamin A, release NO in liver cells, we find inhibition of collagen I and α-smooth muscle actin (α-SMA), fibrogenic genes associated with activated HSCs expression in primary rat liver and human activated HSCs without any obvious cytotoxic effects. Finally, NO-releasing nanoparticles targeted with vitamin A not only attenuate endothelin-1 (ET-1) which elicites HSC contraction but also acutely alleviates haemodynamic disorders in bile duct-ligated-induced portal hypertension evidenced by decreasing portal pressure (≈20%) and unchanging mean arterial pressure. This study clearly shows, for the first time, the potential for HSC targeted nanoparticle delivery of NO as a treatment for liver diseases with proven efficacy for alleviating both liver fibrosis and portal hypertension. Nanoparticles with a typical size of 35 nm are presented for the delivery of nitric oxide to hepatic stellate cells for the potential treatment of liver fibrosis and portal hypertension. The introduction of vitamin A on the nanoparticles surface allows to specifically target hepatic stellate cells. In vivo experiments, using rat models, demonstrate the accumulation of nanoparticles in liver.

Intracellular nitric oxide delivery from stable NO-polymeric nanoparticle carriers

The encapsulation of S-nitrosoglutathione into polymeric nanoparticles substantially improves NO stability in aqueous media without affecting the efficacy of intracellular delivery. The combination of nano-NO delivery and chemotherapy has been found to enhance antitumour activity of chemotherapeutics, as demonstrated using preliminary in vitro experiments with neuroblastoma cells.

A ONE-POT TRANSFORMATION OF KETONES INTO N-(METH)ACRYLOYL-2-AMINO ACIDS

A synthetic sequence for the preparation of N-(meth)acryloyl-2-amino acids is outlined which involves transformation of a ketone successively into an aminonitrile and a (meth)acrylamidonitrile, followed by selective hydrolysis of the nitrile function.All reactions are performed in aqueous media, in one reaction vessel, and in a stepwise manner without isolation of any intermadiate products.